Clinical trials: FL
Non-Hodgkin's Lymphoma
A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
This is a open-label, multicenter, non-randomized, study to evaluate the safety, efficacy, and pharmacokinetics of idasanutlin in combination with obinutuzumab in participants with R/R FL and rituximab in combination with…
- Trial name
- NCT02624986
- Testing
- Idasanutlin, Obinutuzumab, Rituximab
- Where
- 24 sites in United States, Australia and 3 more
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a…
- Conditions
- Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)
- Trial name
- NCT07121946
- Testing
- LTZ-301
- Where
- 6 sites in United States
- Volunteers
- 42 people
- Sponsor
- LTZ Therapeutics, Inc.
Follicular Non-Hodgkin's Lymphoma Refractory
Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma
The primary objective of this study is to assess the overall safety profile of idelalisib monotherapy in patients with refractory follicular lymphoma (FL).
- Trial name
- ZEUS (NCT03568929)
- Testing
- Idelalisib
- Where
- 88 sites in Belgium, France and 8 more
- Volunteers
- 257 people
- Sponsor
- Gilead Sciences
Lymphoma, Follicular
A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma
This 2 stage study will compare the pharmacokinetics and safety profile of subcutaneous and intravenous rituximab in participants with follicular lymphoma.
- Trial name
- NCT00930514
- Testing
- Rituximab
- Where
- 62 sites in Argentina, Australia and 20 more
- Volunteers
- 281 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Follicular
Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present.
- Trial name
- NCT00427856
- Testing
- Obatoclax mesylate, Rituximab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Gemin X
Follicular Lymphoma
A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden
The Alternative-C Trial is a prospective, multicenter Phase 2 Study to evaluate the efficacy of the chemotherapy-free combination of copanlisib and obinutuzumab in patients with previously untreated follicular lymphoma (FL) and a…
- Trial name
- Alternative-C (NCT05387616)
- Testing
- Copanlisib, Obinutuzumab
- Where
- 40 sites in Germany
- Volunteers
- 98 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Non Hodgkin Lymphoma, Follicular Lymphoma
Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL
This study is a Phase 1b, open-label, single arm dose escalation study of Betalutin followed by rituximab in patients with previously treated follicular lymphoma.
- Conditions
- Non Hodgkin Lymphoma, Follicular Lymphoma, Relapsed Follicular Lymphoma
- Trial name
- LYMRIT-37-07 (NCT03806179)
- Testing
- 10 MBq/kg Betalutin, 15 MBq/kg Betalutin
- Where
- 2 sites in Czechia, Norway
- Volunteers
- 7 people
- Sponsor
- Nordic Nanovector
Control arm_Bolstered Care, Treatment arm_HIVRR+S+FL
Kyaterekera Project: A Combination Intervention Addressing Sexual Risk-Taking Behaviors Among Vulnerable Women in Uganda
Guided by Social Cognitive and Asset theories as well as Behavioral Economics (BE) principles,the proposed RCT is carefully designed to test the additive contributions of savings-led microfinance beyond traditional HIV risk…
- Conditions
- Control arm_Bolstered Care, Treatment arm_HIVRR+S+FL, Treatment arm_HIVRR+S+FL+M
- Trial name
- NCT03583541
- Testing
- HIV Risk Reduction, Financial Literacy, Mentorship
- Where
- Uganda
- Volunteers
- 542 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL)
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
This is a phase II study designed to evaluate the toxicity and efficacy of the combination of loncastuximab tesirine and epcoritamab in patients with relapsed/refractory aggressive B-cell lymphoma.
- Conditions
- Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B
- Trial name
- CLEAR (NCT07197307)
- Testing
- Loncastuximab Tesirine and Epcoritamab
- Where
- 34 sites in Germany
- Volunteers
- 120 people
- Sponsor
- Universität Münster
Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with…
- Conditions
- Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL)
- Trial name
- NCT06980116
- Testing
- EXS73565
- Where
- 17 sites in Georgia, Greece and 5 more
- Volunteers
- 85 people
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Non Hodgkin Lymphoma (NHL)
NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma
This trial is an open-label, multicenter, monotherapy, dose-escalation, phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of NB02 (posseltinib) in patients…
- Trial name
- POTENTIAL-M (NCT07114367)
- Testing
- NB02 (Poseltinib)
- Where
- 6 sites in South Korea
- Volunteers
- 9 people
- Sponsor
- NOBO Medicine
Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients…
- Conditions
- Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation), Relapsed/Refractory Mantle Cell Lymphoma (MCL)
- Trial name
- NCT07424833
- Testing
- APG-3288
- Where
- 6 sites in United States, China
- Volunteers
- 180 people
- Sponsor
- Ascentage Pharma Group Inc.
Indolent Non-Hodgkin's Lymphomas
Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
The primary objective of this study is to evaluate the addition of idelalisib to bendamustine/rituximab on progression-free survival (PFS) in adults with previously treated indolent non-Hodgkin lymphoma (iNHL).
- Trial name
- Bridalveil (NCT01732926)
- Testing
- Idelalisib, Rituximab, Bendamustine
- Where
- 144 sites in United States, Australia and 13 more
- Volunteers
- 475 people
- Sponsor
- Gilead Sciences
Relapsed / Refractory Follicular Lymphoma
A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)
The objective of this study is to evaluate the efficacy of TQ-B3525 in patients with relapsed / refractory follicular lymphoma.
- Trial name
- NCT04324879
- Testing
- TQ-B3525
- Where
- 41 sites in China
- Volunteers
- 80 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Follicular Lymphoma, Small Lymphocytic Lymphoma
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas
The primary objective will be to assess the overall response rate and to evaluate the efficacy and safety of idelalisib (IDELA; GS-1101) in participants with previously treated indolent Non-Hodgkin Lymphoma (iNHL) that is…
- Conditions
- Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma
- Trial name
- DELTA (NCT01282424)
- Testing
- Idelalisib
- Where
- 41 sites in United States, France and 4 more
- Volunteers
- 125 people
- Sponsor
- Gilead Sciences
Fetal Growth Restriction
Prediction of Growth Restricted Fetuses Using Femur Length to Mid-thigh Circumference Ratio: A Case-control Study
One of the most challenging areas currently facing obstetricians is the detection and management of pregnancies in which the growth of the fetus is poor.
- Trial name
- IUGR (NCT01981824)
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ain Shams Maternity Hospital
Growth of Infants
Addition to Infant Formula of 2-fucosyllactose (2-FL)
OBJECTIVES: Primary: The primary objective is to determine whether the mean weight gain over a 16-week interval starting on or before 14 days of life differs between infants fed one of two infant formulas as their sole source of…
- Trial name
- 2-FL (NCT03109223)
- Testing
- sole source nutrition
- Where
- 6 sites in United States, Honduras
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- PBM Nutritionals
CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL)
Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies
Current treatments for relapsed/refractory hematopoietic malignancies such as B-cell lymphomas (BCLs) and peripheral T-cell lymphomas (PTCLs) are far from satisfactory.
- Conditions
- CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Diffuse Large B-cell Lymphoma (DLBCL)
- Trial name
- NCT04767308
- Testing
- CT125A cells, Cyclophosphamide, fludarabine
- Volunteers
- 18 people
- Sponsor
- Huazhong University of Science and Technology